Rhythm Pharmaceuticals Inc (RYTM) Stock Analysis
Verdict: WATCH (do not buy)
IMCIVREE expansion drives 50%+ top-line growth, but high valuation (28.6x P/S) and deep net burn leave zero room for clinical slip-ups.
Investment score: 57/100
Analysis as of
Is Rhythm Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The model rates RYTM as a HOLD. While IMCIVREE commercial acceleration and pipeline readouts provide strong multi-year fundamentals, current valuation at 28.6x P/S reflects much of the near-term pipeline success.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 62/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 58/100 (weight 15%)
Rhythm Pharmaceuticals Inc opportunities and risks
What speaks for RYTM
- Commercial ramp of IMCIVREE in Bardet-Biedl Syndrome (BBS) and POMC/PCSK1/LEPR deficiencies.
What speaks against RYTM
- Clinical trial failure or regulatory delay in pipeline expansion indications.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RYTM | n/a | 28.6x | n/a | 89.0% | -85.6% | -2.2% |
| CAI | 82.2x | 8.7x | 48.7x | 69.7% | 10.6% | 1.7% |
| IONS | n/a | 8.9x | 2.3x | 98.2% | -64.6% | -7.1% |
| IMVT | n/a | 1079.7x | n/a | 97.1% | -7585.9% | -5.4% |
| CGON | n/a | 1065.7x | n/a | -82.7% | -3602.7% | -2.7% |
| MIRM | n/a | 9.7x | n/a | 81.7% | -139.2% | -7.7% |
| Peer median | n/a | 9.7x | n/a | 81.7% | -139.2% | -5.4% |
Frequently asked questions about Rhythm Pharmaceuticals Inc (RYTM)
Is RYTM stock a good investment?
The TradeMates model rates Rhythm Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 57/100. The model rates RYTM as a HOLD. While IMCIVREE commercial acceleration and pipeline readouts provide strong multi-year fundamentals, current valuation at 28.6x P/S reflects much of the near-term pipeline success. This is algorithmic model output, not personal investment advice.
Is RYTM stock a buy?
The TradeMates model verdict for RYTM is WATCH (do not buy) with an investment score of 57/100. Treat this as a model signal to review, not a personal buy recommendation.